Department of Developmental Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA, United States of America.
Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, United States of America.
Neurobiol Dis. 2022 Jul;169:105722. doi: 10.1016/j.nbd.2022.105722. Epub 2022 Apr 8.
The 2021 VCP Scientific Conference took place virtually from September 9-10, 2021. This conference, planned and organized by the nonprofit patient advocacy group Cure VCP Disease, Inc. (https://www.curevcp.org), was the first VCP focused meeting since the 215th ENMC International Workshop VCP-related multi-system proteinopathy in 2016 (Evangelista et al., 2016). Mutations in VCP cause a complex and heterogenous disease termed inclusion body myopathy (IBM) with Paget's disease of the bone (PDB) and frontotemporal dementia (FTD) (IBMPFD), or multisystem proteinopathy 1 (MSP-1) Kimonis (n.d.), Kovach et al. (2001), Kimonis et al. (2000). In addition, VCP mutations also cause other age-related neurodegenerative disorders including amyptrophic lateral sclerosis (ALS), Parkinsonism, Charcot-Marie type II-B, vacuolar tauopathy among others (Korb et al., 2022). The objectives of this conference were as follows: (1) to provide a forum that facilitates sharing of published and unpublished information on physiological roles of p97/VCP, and on how mutations of VCP lead to diseases; (2) to bolster understanding of mechanisms involved in p97/VCP-relevant diseases and to enable identification of therapeutics to treat these conditions; (3) to identify gaps and barriers of further discoveries and translational research in the p97/VCP field; (4) to set a concrete basic and translational research agenda for future studies including crucial discussions on biomarker discoveries and patient longitudinal studies to facilitate near-term clinical trials; (5) to accelerate cross-disciplinary research collaborations among p97/VCP researchers; (6) to enable attendees to learn about new tools and reagents with the potential to facilitate p97/VCP research; (7) to assist trainees in propelling their research and to foster mentorship from leaders in the field; and (8) to promote diversity and inclusion of under-represented minorities in p97/VCP research as diversity is critically important for strong scientific research. Given the range of topics, the VCP Scientific Conference brought together over one hundred and forty individuals representing a diverse group of research scientists, trainees, medical practitioners, industry representatives, and patient advocates. Twenty-five institutions with individuals from thirteen countries attended this virtual meeting. In this report, we summarize the major topics presented at this conference by a range of experts.
2021 年 VCP 科学会议于 2021 年 9 月 9 日至 10 日虚拟举行。该会议由非营利性患者权益组织 Cure VCP Disease, Inc.(https://www.curevcp.org)策划和组织,是自 2016 年第 215 届 ENMC 国际研讨会(Evangelista 等人,2016 年)以来首次专门针对 VCP 的会议。VCP 突变导致一种复杂且异质的疾病,称为包涵体肌病(IBM)伴骨 Paget 病(PDB)和额颞叶痴呆(FTD)(IBMPFD),或多系统蛋白病 1(MSP-1)Kimonis(n.d.),Kovach 等人。(2001 年),Kimonis 等人。(2000 年)。此外,VCP 突变还导致其他与年龄相关的神经退行性疾病,包括肌萎缩侧索硬化症(ALS)、帕金森病、Charcot-Marie 型 II-B、空泡 tau 病等(Korb 等人,2022 年)。本次会议的目标如下:(1)提供一个论坛,促进分享有关 p97/VCP 的生理作用以及 VCP 突变如何导致疾病的已发表和未发表信息;(2)增进对与 p97/VCP 相关疾病相关机制的理解,并能够确定治疗这些疾病的疗法;(3)确定 p97/VCP 领域进一步发现和转化研究的差距和障碍;(4)为未来的研究制定具体的基础和转化研究议程,包括关于生物标志物发现和患者纵向研究的关键讨论,以促进近期临床试验;(5)加速 p97/VCP 研究人员之间的跨学科研究合作;(6)使与会者了解具有促进 p97/VCP 研究潜力的新工具和试剂;(7)帮助受训人员推进他们的研究,并从该领域的领导者那里获得指导;(8)促进 p97/VCP 研究中代表性不足的少数群体的多样性和包容性,因为多样性对于强大的科学研究至关重要。鉴于主题广泛,VCP 科学会议汇集了来自 140 多名代表不同研究领域的科学家、受训人员、医疗从业者、行业代表和患者权益倡导者。来自 13 个国家的 25 个机构的个人参加了这次虚拟会议。在本报告中,我们总结了会议上由一系列专家介绍的主要议题。